Leader in Pharmaceutical Oral Films

IntelGenx

WE MAKE APPROVED DRUGS BETTER
Our Mission

We make approved drugs better, with next generation pharmaceutical products that address unmet medical needs, and offer significant benefits to patients and physicians.
IntelGenx is a leading oral drug delivery company focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

• Established in 2003.
• 25 years+ experience in oral films.
• Offices & manufacturing facilities based in Montreal, Canada.
• Listed on the TSX-V and OTC-QX.

Our Core Values

- Customer Orientation
- Teamwork & Collaboration
- Honesty & Openness
- Innovation & Creativity
- Accountability
- Respect

WE MAKE APPROVED DRUGS BETTER
OUR ADVANTAGE

We offer a full range of services in oral film development and manufacturing while expanding our own product pipeline.

- **R & D:** Our team of highly qualified researchers is extremely versatile, creative and efficient in developing innovative products protected by strong intellectual property.

- **Intellectual Property:** The VersaFilm™ technology platform and products are protected by several issued patents and pending applications.

- **Regulatory & Quality:** Our knowledgeable regulatory team monitors project development closely in order to ensure GMP compliance and a smooth transition from R&D to regulatory approval and commercial manufacturing.

- **Manufacturing:** IntelGenx’s highly skilled team demonstrates technological expertise in scale-up, technology transfer and manufacturing of pharmaceutical oral thin films.
The IntelGenX Advantage

Our focus, expertise, creativity and responsiveness in oral film development enable us to offer our partners a full range of services that deliver high quality and cost effective products.
VERSAFILM™ ORAL FILM

- VersaFilm™ is our proprietary delivery technology platform that enables the development of pharmaceutical oral films with potential to improve absorption, accelerate onset of action, reduce side effects, ease administration and improve patient compliance.

- IntelGenx® patented VersaFilm™ oral films are customized to provide solutions to unmet needs for patients, physicians and caregivers, while providing commercial opportunities to our partners.
DIVERSIFIED PRODUCT PORTFOLIO

- We have a robust product pipeline based on our VersaFilm™ proprietary technology platform.
- We focus on innovation.
- Our ambition is to develop products that address unmet medical needs and offer better patient outcomes.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Partnering Status</th>
<th>Formulation Development</th>
<th>Pilot Study</th>
<th>Pivotal Study</th>
<th>Filing</th>
<th>Launch</th>
<th>Partner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Migraine - Rizaport™ (Rizatriptan)</td>
<td>Available ex-Spain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cephalon</td>
</tr>
<tr>
<td>Erectile Dysfunction (Tadalafil)</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cephalon</td>
</tr>
<tr>
<td>Schizophrenia (Loxapine)</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cephalon</td>
</tr>
<tr>
<td>Central Nervous System (Montelukast)</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cephalon</td>
</tr>
<tr>
<td>Opioid Dependence (Buprenorphine/Naloxone)</td>
<td>Available ex-U.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PAR Pharmaceuticals</td>
</tr>
<tr>
<td>Undisclosed</td>
<td>Available ex-U.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chemo</td>
</tr>
<tr>
<td>Undisclosed</td>
<td>Available ex-U.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chemo</td>
</tr>
<tr>
<td>Central Nervous System</td>
<td>Available</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Undisclosed</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Undisclosed</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Partnered</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Undisclosed</td>
</tr>
</tbody>
</table>
STRATEGY

We focus on areas where oral films are particularly well-suited, creating high-value differentiated product opportunities for our partners.

Lifecycle management

Successful lifecycle planning can extend the sales of existing products, while opening new avenues for growth.

Tangible patient benefits

VersaFilm™ oral films are developed to address unmet needs:

- Faster onset of action and increased bioavailability.
  - Quicker buccal or sublingual absorption.

- Reduced side effects.
  - Avoidance of first pass metabolism.

- Enhanced compliance.
  - Rapid disintegration without the need for water.
  - Ease of administration for patients who have problems swallowing: pediatric, geriatric, fear of choking and/or suffering from nausea.

- Convenience.
  - Pleasant taste.
  - Unidose packaging to carry-on the-go.
  - Discreet postage stamp dimension.

Drug repurposing

We have experience with repurposing drugs for new indications and generating associated intellectual property protection.

Generics

IntelGenx® team has a demonstrated track record of developing generics of branded products with high technology barriers to entry.
WE HAVE A PROVEN TRACK RECORD

Rizaport™ is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines which has been granted a European marketing authorization.

- Rizaport™ represents an attractive therapeutic alternative for migraine patients.
- The thin film disintegrates rapidly without the need for water, has a pleasant taste, and its pocket size makes it ideal for migraine sufferers to carry-on-the-go.
- Patients can also take their medication without exacerbating nausea, one of the most important attributes when selecting a product to treat migraine headaches.

IntelGenx successfully developed a generic formulation of buprenorphine and naloxone sublingual film indicated for the maintenance treatment of opioid dependence.

- An Abbreviated New Drug Application (ANDA) was filed at the U.S. FDA by our U.S. based co-development and commercialization partner Par Pharmaceutical.
- The submission was accepted for review at the U.S. FDA.
- The reference listed drug is Suboxone® (buprenorphine and naloxone) sublingual film.
WE OFFER FULL SERVICE CAPABILITY TO FOSTER THE GROWTH OF OUR PARTNERS

• Our state-of-the-art facilities are equipped with the most modern equipment to deliver high-quality, cost-effective products, while accommodating client requirements at every product development stage.

• IntelGenx™ manufacturing plant, established to support the VersaFilm™ technology platform, provides lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients:

R&D LAB-SCALE
Together with our formulation specialists, our R&D development laboratories are fitted with high-tech equipment and tools for the formulation and development of innovative oral thin film pharmaceuticals.

SCALE-UP & TECHNOLOGY TRANSFER
Our oral film experts manage IntelGenx™ modern and customized equipment to allow for a proportional parametric transfer from small to large scale production, facilitating manufacturing development processes.

COMMERCIAL MANUFACTURING
Our team’s unique experience with large scale production of thin films, including high viscosity blends, suspensions and monolayer or multilayer film products, provides significant advantages to our customers.
MANUFACTURING & PACKAGING

Cutting-edge manufacturing equipment:
- Solvent safe blending tanks to produce both aqueous and solvent-based coating mass.
- Coating lines with variable coating techniques and widths to match product requirements.
- Versatile slitting units to optimize yields.

High-speed packaging:
- Die-cut films of desired shape and size.
- Unidose packaging of films into pouches.
- Individually identified films and pouches.

- Our equipment and procedures have been designed to comply with all regulatory standards. Our cGMP facility is dedicated to the development and manufacturing of pharmaceutical oral films. We are licensed to handle narcotics and controlled substances.
- We assess all critical process parameters during the development process of your product using Design of Experiments (DOE) methodology to:
  - Accelerate processes,
  - Reduce costs,
  - Mitigate risks.
WE MAKE APPROVED DRUGS BETTER

To partner with us, please contact our business development department:

bdcontact@intelgenx.com

+1 514 331 7440 Ext 212

IntelGenx Corp. 6420 Abrams, Saint-Laurent, Quebec, Canada H4S 1Y2

+1 514 331 7440

www.IntelGenx.com